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Warfarin inhibits metastasis of Mtln3 rat mammary carcinoma without
affecting primary tumour growth
P. McCulloch & W.D. George
University Department of Surgery, Western Infirmary, Glasgow, UK.
Summary Coumarin anticoagulants inhibit metastasis in several animal models, but the mechanism of this
effect is uncertain. In order to determine the role of cytotoxic and/or cytostatic actions of coumarins on the
tumour cells, we have studied the effects of warfarin on tumour cell growth in a model in which tumour
metastasis is inhibited by this drug. Clonogenic assay, growth curve analysis and thymidine labelling index
revealed that warfarin had no effects on Mtln3 mammary carcinoma cell growth in vitro at concentrations
below 1 mm. The growth rate of subcutaneously implanted Mtln3 tumour deposits in female F344 rats,
assessed by weight and by stathmokinetic analysis of the tumour tissue, was identical in warfarin-treated and
control animals. Spontaneous metastasis from such tumours to the lungs was, however, significantly reduced
in warfarin-treated animals (median 0 pulmonary tumours per animal in warfarin treated, eight tumours per
animal in control animals; P<0.05, Mann-Whitney). The mean plasma warfarin concentration in warfarin
treated rats was 1.63 M. These results suggest that warfarin treatment of the host animal can inhibit tumour
metastasis without having any direct or indirect effect on the growth rate of the tumour cells.
Current theories (Hart, 1980; Poste & Fidler, 1980) view
metastasis as a multistep process in which successive
obstacles are overcome by a small subpopulation of tumour
cells capable of doing so. Each step requires different
properties, and each influences subsequent steps. This com-
plex process cannot be studied as a single unit, but requires
subdivision: one way in which this can be achieved is to
study influences that increase or decrease metastasis, and to
attempt to define the point at which they have their effect.
The coumarin group of anticoagulant drugs, including war-
farin, represent an example of such an influence. Coumarins
inhibit metastasis in several animal models (Ryan et al.,
1969; Brown, 1973; Hilgard et al., 1977; Williamson et al.,
1980). There is an extensive literature documenting the
existing of coagulation disturbances in human cancer (Davis
et al., 1969; Sun et al., 1979; Rickles & Edwards, 1983;
Mannucci et al., 1985), and suggestive evidence of a role for
coagulation in the spread and growth of tumours (Dvorak et
al., 1979; Goeting et al., 1985; McCulloch & George, 1987).
Studies by Zacharski et al. (1984) have demonstrated the
beneficial effect of anticoagulant treatment with warfarin on
the survival time of patients with small cell lung cancer.
Evidence from the studies of Hilgard & Maat (1979) and
Colucci et al. (1983), however, suggests that the antimeta-
static effect of coumarins may not be mediated via their
anticoagulant activity. Coumarins have been shown to in-
hibit the expression of a procoagulant molecule produced by
tumour cells, but the relevance of this to their effects on
metastasis remains uncertain (Colucci et al., 1983). The
possibility that coumarins have cytotoxic properties has been
investigated in several different models (Boulos, 1971;
Higashi & Heidelberger, 1971; Brown, 1973; Chang & Hall,
1973; Dolfini et al., 1979; McNeil et al., 1984) with diverse
results. The variety of models employed and the frequent use
of in vitro measures of cytotoxicity without reference to the
effects of the drugs in vivo make interpretation of these
studies particularly difficult. Several studies have noted a
possible suppressive effect of coumarin treatment on primary
tumour growth (Ryan et al., 1968, 1969; Hilgard et al.,
1977), but have used only crude methods which are prone to
random error. Only one study has attempted to combine in
vitro studies of cytotoxicity and in vivo assessment of drug
effects on tumour growth and metastasis (Brown, 1973) and
the metastatic behaviour of the tumour model used makes
interpretation of this study difficult. It therefore remains
uncertain whether coumarin treatment inhibits metastasis
Received 3 July 1988, and in revised form, 26 September 1988.
specifically, or has a more general effect on tumour growth.
We have addressed this question by combining a study of
the in vitro cytotoxicity of warfarin with experiments on the
effects of the drug on both primary tumour growth and




Female Fischer 344 rats (Olac Ltd, Bicester, England), 6-8
weeks old, were used. Animals were fed a standard diet
(CRM Diet, Labsure, Cambridge, England) and tap water
with a chlorine content of 7mg-1. All animals were normal
and healthy according to visual observations and to the
results of routine microbiological testing for infection. The
mean weight of the animals was 140g.
Tumour cells
The tumour cells used were a clone of rat mammary
carcinoma designated Mtln3, originally derived from the
7.12-dimethylbenz(a)anthracene-induced adenocarcinoma
13762 (Segaloff, 1966). This clone was derived from the
parent tumour by Neri & Nicolson (1981) and was charac-
terised as being of high metastatic potential. Cells were
cultured in 75cm2 tissue culture flasks (Nunc, Paisley,
Scotland) in equal parts of Hams' FIO and Dulbecco's
Modified Eagles' Medium (F1O/DMEM), with 10% fetal calf
serum (FCS) but without antibiotics. Cultures were main-
tained at 37°C in equilibrium with 2% CO2 in air. Cultures
were passaged when they approached confluence by the use
of Ca2+ and Mg2+ free phosphate buffered saline containing
1 mM EDTA followed by 0.25% trypsin (Gibco, Paisley,
Scotland). Subculture was carried out by the addition of
3 x 106 viable cells to further 75cm2 flasks. Cells were
passaged a maximum of six times between thawing and use,
to minimise problems of phenotypic drift (Neri & Nicolson,
1981). Multiple subcultures of the cell line were stored in
liquid nitrogen at - 196°C and fresh cultures were begun
from these as required. Inocula of 106 cells from our stock
cultures injected into the mammary fat pad of Fischer rats at
the beginning and at the end of this series of experiments
showed no change in the metastatic potential of the line.
In vitro studies of warfarin cytotoxicity
The cytotoxic effect of warfarin sodium on the Mtln3
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tumour cell was studied using three techniques: clonogenic
assay, growth curve analysis and thymidine labelling assay.
Clonogenic assay Mtln3 cells from a culture in log growth
phase were trypsinised as described, washed three times in
F10/DMEM with FCS by centrifugation at 200g for 5
minutes, and prepared as a monocellular suspension in the
same medium at 104 cellsml-1. Warfarin sodium powder
(WB Pharmaceuticals, Bracknell, England) was dissolved in
F10/DMEM + FCS to form a 10mM solution, which was
resterilised by passage through a 0.2pm filter. Serial dilu-
tions of this solution were added to the tumour cells as
required to produce cell suspensions at a density of 200 cells
ml-1 at warfarin concentrations ranging from 10mm to
10-4pM. Quadruplicate cultures were made at each concen-
tration in 60mm tissue culture Petri dishes (Nunc, Paisley,
Scotland) and incubated for eight days. Cultures were then
fixed and stained with 0.5% crystal violet, and colony counts
made. Cloning efficiency was reported as the percentage of
control efficiency.
Growth curves Mtln3 cells were trypsinised and prepared as
described above, and adjusted to a final density of 104 cells
ml-' in F10/DMEM+FCS. Cultures were prepared at this
density in 35mm Petri dishes using 3 ml per dish. Three
groups of cultures were used; a control group, incubated
with no warfarin; a group incubated in 10pM warfarin and a
group incubated in 1 mM warfarin. Cultures were incubated
at 37°C, and the total cell count assessed in triplicate dishes
from each group on days 1, 2, 3, 4, 6, 8 and 9 after
initiation, using a Coulter model ZB cell counter, and
counting the trypsinised cells resuspended in a standard
volume of phosphate buffered saline (PBS). Cultures were
fed every 48h by removal of 2ml of the overlying medium
and replacement with fresh medium containing the same
amount of warfarin.
Thymidine labelling index Mtln3 cells were prepared at
5 x 104 cells ml- 1 in F10/DMEM +FCS, and were seeded
onto 'Thermanox" plastic cover slips (Miles Laboratories,
Napersville, IL), contained in the 16mm wells of 24-well
tissue culture plates (Nunc, Paisley, Scotland). Three groups
of culture were prepared as for growth curves, at warfarin
concentrations of 0, 10, M and 1 mm. Cells were incubated at
37°C and fed every 48 h by replacement of 2/3 of the
overlying medium, while daily observation of their growth
was carried out using an inverted phase contrast microscope.
On day 4, when the cells in the control group appeared to
be in mid-log phase, triplicate cultures from each treatment
group were pulsed for 20min with 3H-thymidine ([6-3H]
thymidine, Amersham, Bucks., England). 150 4ul of 0.25mM
thymidine, specific activity 20-30 CimM - 1 (0.74-
1.1 TBlmmv- 1) was added to each culture, giving a final
activity of 5pCiml-1 (0.185MBlml-1). Cells were then fixed
in methanol/trichloracetic acid. The coverslips bearing the
fixed cells were then coated with liquid photographic emul-
sion and placed in light-tight boxes for 14 days. After
development of the emulsion, cell morphology was outlined
by counterstaining with Giemsa stain (1:10 dilution). The
thymidine labelling index (TLI) was estimated by counting
nuclei in random high-power ( x 400) microscope fields. Cells
were deemed to be positively labelled if there was a definite
cluster of five or more silver granules overlying the nucleus.
A total of 1,000 nuclei per coverslip were counted, and the
TLI was expressed as the number of labelled nuclei divided
by the total number of nuclei counted.
Anticoagulation
As noted by previous authors (Williamson et al., 1980),
maintenance of a steady level of anticoagulation in the rat
using warfarin is difficult, and requires frequent measure-
ment of the effect, with ad hoc adjustment of the dose. After
several pilot studies, the following procedure was adopted:
warfarin was administered in the drinking water at a con-
centration of 2mgI-1 for 48h, then at lmgl - for 24h.
Thrombotest (Nyegaard, Oslo, Norway) estimations were
then performed on three rats from each group, using 50p1 of
free flowing blood. Dose adjustments were aimed at main-
taining the Thrombotest within the range 68-170s (16-4%
of rat normal activity). No tumour experiment was begun
until the median thrombotest result had been within this
range for 24 h. Regular Thrombotest estimation was then
carried out on three rats from the treated group every three
days in experiment 1 (see below) and every two days in
experiment 2. An identical blood sample was taken from
three rats in the control group at the same times. Warfarin
was given continuously, with the dosage adjusted as
required, until killing at 23 days after tumour cell injection.
Experiment 1: effect of warfarin on primary tumour growth
Two groups of 15 rats were inoculated subcutaneously with
106 Mltn3 cells per animal. The cells were prepared as
previously described from low-passage cultures in vitro, and
resuspended at a density of 5 x 106 cells per ml in FIO/
DMEM+FCS. All animals received injections of 0.2ml of
the cell suspension into the infra-mammary fat pad under
the second nipple. One group received no treatment, the
other received oral warfarin as detailed above. Animals were
killed 23 days after tumour cell injection, at which time a
stathmokinetic analysis of tumour cell production rate was
performed. The tumours were excised together with the
overlying skin and weighed fresh, after trimming off all
normal tissue and opening and draining cystic spaces con-
taining mucoid material, which were commonly found at the
centre of these tumours. The tumours were then fixed in
Bouins' solution for 24h, and thin (5ytm) sections across the
geometric centre of the tumour were made and stained with
Haematoxylin and Eosin. These sections were used to per-
form a stathmokinetic analysis (Puck & Steffen, 1963). In
this experiment, vincristine was administered in a dose of
1 mg kg- intraperitoneally. After injection, animals were
killed by cervical dislocation at intervals of 10 or 15min for
up to three hours after injection. After killing, the tumours
were removed, weighed, fixed and sectioned as previously
described. Each section was examined in a standard way to
minimise differences between tumours in the kinetic activity
of the areas examined, and 40 microscope fields were
defined, which lay in a circle around the tumour centre at a
distance of 2/3 of the tumour radius. Counting of nuclei was
carried out using an eyepiece graticule, and the ratio
(number of nuclei in metaphase/total number of nuclei) was
calculated. In this way 2,400 points were counted per slide.
The method was validated by studying the effect on the
metaphase ratio of taking progressively larger samples of the
cell population on a single slide. This showed that a
considerable degree of random error was found in the result
when low numbers of nuclei were counted, but that this
variability gradually disappeared as the sample became
larger.
Experiment 2: effect of warfarin on spontaneous metastasis
Two groups of 15 rats were inoculated subcutaneously with
106 Mtln3 cells per animal, as described in experiment 1. One
group of rats received no treatment, the other received oral
warfarin as detailed above. Animals were killed at 23 days,
and pulmonary metastases estimated by the method of
Wexler (1965). Briefly, this involves en bloc excision of the
heart and lungs from the killed animal and inflation of the
lungs via the trachea with a 15% solution of India ink. The
lungs are immersed in Fekete's solution for at least 48h to
bleach surface pulmonary tumour nodules, which are then
counted. All lungs were examined twice by the same
observer, who was unaware of the treatment that the animal
had received. Full autopsy was performed at the time of
killing, and any suspected sites of extrapulmonary metastasis
noted and, where necessary, confirmed by histological exam-
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Results
Studies in vitro
Clonogenic assay Warfarin inhibited clone formation by
Mtln3 cells only at high concentrations. Warfarin concen-
trations of less than 1 mM had no discernible effect on the
clonogenic potential of the cells. Figure 1 shows the clono-
genic potential of the cells at different drug concentrations.
Estimates of the probable peak warfarin concentrations in
fully anticoagulated rats were made, based on the studies of
previous authors: these suggested that the plasma concen-
tration of the drug is unlikely to exceed 10 M. Subsequent
direct measurement of plasma warfarin concentrations in
identically treated animals showed a mean warfarin concen-
tration of 1.63pM, confirming this estimate.
Growth curve The increase in cell numbers over time
followed the conventional pattern of large phase, exponential
growth phase and plateau phase. Neither the rate of increase
in cell numbers nor the timing or height of the plateau were
affected by 10JM warfarin, but 1 mM warfarin affected both
parameters considerably (Figure 2).
Thymidine labelling index The thymidine labelling index
(TLI) of cells in the control and lOpM warfarin groups was
high, averaging over 40%. In keeping with the results of the
other two experiments, however, cells grown in the presence
of I mM warfarin grew Very poorly. The mean TLI in the
control group was 44.8% and in the 10pM warfarin group
45.1%. Insufficient cells grew in the 1 mM warfarin group to
allow an accurate TLI to be estimated.
Warfarin anticoagulation
The method of warfarin administration used successfully
suppressed the coagulation system of the animals to an
extent similar to that achieved during clinical anticoagulation
in humans. The mean Thrombotest clotting time in anti-
coagulated animals during experiment 1 was 144s, and
during experiment 2, 84.4s, compared with a mean for
untreated animals of 30.3s (s.d. 1.03s). There were marked
fluctuations from day to day in the mean Thrombotest time
of treated animals, but it remained within the calculated
'therapeutic range' of 68-170s for 66% of the study time in
experiment 1, and for 57% in experiment 2. There were five
deaths from haemorrhage among the animals in the warfarin












Figure 2 The effects of IO Mm and of 1 mM warfarin on the
growth of Mtln3 rat mammary carcinoma cells in vitro. Open
circles represent untreated control cultures, closed circles the
cultures exposed to 10Mm warfarin and open squares the cultures
exposed to 1 mM warfarin. Error bars show one standard
deviation.
monitoring was introduced for experiment 2, and two ani-
mals died from haemorrhage. Subsequent experience has
shown that long-term warfarin treatment is associated with
an unavoidable 10-15% mortality in this model, regardless
of the monitoring system employed.
Experiment I
The mean tumour weight in the control and experimental
groups was very similar. Warfarin-treated animals produced
tumours with a mean weight of 12.03g (s.d. 1.61 g); the
corresponding values for control animals were 11.38g and
1.1 g. There is no significant difference between these results.
The sampling method for estimating the metaphase ratio of
the tumours was validated by cumulative counting of nuclei
from a single slide. The metaphase ratio was re-estimated
after each additional 50 metaphases, and stabilised at
approximately 8.1% after between 150 and 200 metaphases
had been counted (TableI). As a result of this study, it was
decided to count 2,400 points on each slide in the study
groups undergoing stathmokinetic analysis, since this repre-
sented approximately 200 metaphases at the mid-point of the
linear segment of the stathmokinetic curve. The results of
this exercise are illustrated in Figure 3. Comparisons of the
size of normal and metaphase nuclei and of the cytoplasm/
nuclear area ratio in the two groups showed no detectable
differences between them and the crude metaphase ratios
were therefore used. As Figure 3 shows, the estimated cell
production rate calculated from the gradient of the meta-
phase number/time curve was identical in the two groups, at
3.9 metaphases per 100 cells per hour.
Table I Variation in metaphase ratio with metaphase count
Metaphase count 50 100 150 200 250 300 350 400
Metaphase ratio 6.90 7.80 7.50 8.10 8.20 8.20 8.20 8.30
-4 -3 -2 -1 0 1 2 3 4
Log1o (warfarin concentration) p.m
Figure 1 The effect of warfarin concentration on the clonogenic
potential of Mtln3 rat mammary carcinoma cells. Survival
fraction is expressed as a ratio of the survival fraction in a
control assay containing no warfarin.
Experiment 2
There was a considerably lower rate of metastasis to the lung
in the warfarin-treated rats than in control animals, as
illustrated in Figure 4. The median number of lung metas-
tases per animal in group 1 was 0 (range 0-21), while in
group 2 it was eight tumours per animal (range 0-133). In
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Figure 3 Stathmokinetic analysis of cell production rate in
Mtln3 tumours: effect of warfarin treatment of the host animal.
Each point represents one tumour: the x axis indicates the time
between vincristine injection and killing 0 control;
0 ----, warfarin treatment. Tumour wet weight: control
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Figure 4 Metastasis to the lungs from subcutaneous Mtln3
mammary tumours in (a) control and (b) warfarin treated
animals.
the treatment group seven animals and in the control group
three animals had no detectable pulmonary metastasis. The
difference between the two groups was statistically significant
(P<<0.05, Mann-Whitney). Macroscopic and selective histo-
lmnical cxamination of other organs removed at autopsy
failed to reveal any instance of metastasis to viscera other
than the lungs, although the regional and mediastinal lymph
nodes were commonly involved in animals from both treat-
ment and control groups, with no detectable difference
between the two.
Discussion
These experiments represent the first fully integrated study of
the cytotoxic effects of warfarin in vitro and in vivo. This
combined approach is necessary in order to define the role
of cytotoxicity in the antimetastatic action of warfarin,
because of the weaknesses of isolated studies of either type.
In vitro studies cannot reproduce the complexity of inter-
actions between drug, tumour and host in the intact animal.
Known factors of this type in the present case include the
production of a number of abnormal proteins, the PIVKAs
(Stenflo & Suttie, 1977), as a result of warfarin-induced
suppression of vitamin K activity, and the synthesis of a
number of metabolites of warfarin by the host liver
(O'Reilly, 1985). These or other interactions might produce
substances with a direct antitumour activity, and in vitro
studies alone would not be capable of detecting such indirect
but important results of warfarin treatment. The short-
comings of in vitro studies in this respect have recently been
demonstrated by Fasco et al. (1987), who have shown that
the effect of warfarin on tumour procoagulant activity is
indirect, and is at least partly due to modulation of the
metabolism of the host animal. Animal experiments, on the
other hand, are subject to numerous extraneous influences,
the effects of which can only be controlled by careful
experimental design. Previous studies of the effect of cou-
marins on primary tumour growth have used crude estimates
of tumour mass, which may be greatly influenced by changes
in the bulk of the tumour stroma and in the degree of
invasion by host macrophages, as well as by changes in
tumour cell division and death rates. A more accurate
method of assessing the effects of warfarin on tumour cell
production rate was therefore adopted. The specific ability of
coumarins to inhibit metastasis has been emphasised in
many previous studies; in order to determine whether this
ability is attributable to general inhibition of tumour growth,
it was important to study the effects of warfarin on metasta-
sis and primary tumour growth in the same model, under the
same circumstances.
The cytotoxic effect of warfarin on the Mtln3 clone was
tested using three complementary in vitro methods, the
results of which were in full agreement. In clonogenic assay,
growth curve and thymidine labelling studies, warfarin
sodium at a concentration of 1 mM suppressed tumour cell
growth very significantly. At a concentration of 10,iM, on
the other hand, the drug had no detectable effect on clone
forming potential, net cell production rate or incorporation
of labelled thymidine. Calculation and direct measurement of
the mean plasma warfarin concentration in rats treated with
oral warfarin showed that drug concentrations in excess of
10 gM would be most unlikely to occur in vivo. It seems
reasonable to conclude that any effect of warfarin treatment
on the in vivo behaviour of the Mtln3 tumour cell clone is
not due to the direct antitumour activity of the drug.
Warfarin anticoagulation reduced metastasis significantly
in our in vivo studies, but failed under similar conditions to
exert any detectable effect on primary tumour growth. The
effect on metastasis was not as dramatic as that seen when
tumour cells were injected intravenously in the same model
system (McCulloch & George, 1987) but was consistent on
subsequent repetition of the experiment. These findings are
in agreement with those of Colucci et al. (1983), but contrast
with those of other workers (Ryan et al., 1968; Hilgard et
al., 1977). Several of these previous studies used mouse
models, in which a very much higher degree of anticoagula-
tion could be achieved, and this may explain their contrast-
ing outcomes. The results of stathmokinetic analysis in our
study were particularly striking. The calculated indices of cell
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cally identical, providing convincing evidence that warfarin
had no effect on cell production in vivo in this model. The
stathmokinetic technique is susceptible to a number of
sources of error (Aherne et al., 1977) but precautions taken
in the design of the experiment appear to have been
successful in minimising such influences. The marked inhibi-
tion of metastasis by the drug under the same conditions
therefore appears to represent a direct effect on the meta-
static process, as opposed to one mediated via cytotoxic to
cytostatic actions. An effect of warfarin on the Mtln3
tumour cells other than one on cell reproduction is not
excluded by our findings. The reports of Colucci et al.
(1983), describing a warfarin-sensitive procoagulant molecule
produced by tumour cells, may be of relevance in this
respect. It is possible that this, or some other warfarin-
sensitive process within these cells, is important in enhancing
their metastatic capability. Our previous studies in a modi-
fied version of this model, however, suggest that the princi-
pal antimetastatic effect of warfarin is on the host, as
opposed to the tumour cell (McCulloch & George, 1987).
Rats are extremely sensitive to the anticoagulant effects of
warfarin and other coumarins, and oral treatment with these
drugs is therefore difficult (Williamson et al., 1980). The
relative degree of anticoagulation achieved in this study was
very similar to that achieved therapeutically in humans, but
the high mortality clearly indicates the greater susceptibility
of rats to fatal haemorrhage after the same degree of
anticoagulation. This difference is probably due to inter-
species differences in the hepatic metabolism of PIVKAs
(Suttie, 1980). Intensive monitoring of the anticoagulant
effect of warfarin reduced but did not prevent deaths from
bleeding, as the result of experiment 2 illustrated. Death
from warfarin overdosage appeared to be a sudden cata-
strophic event, and there was no evidence of prior weight
loss, reduced food intake or changed behaviour in the
animals that died. It therefore seems improbable that an
effect of warfarin on the general health of the animals could
have been responsible for the observed changes in tumour
behaviour. The tumours of animals dying from bleeding
were not significantly larger or smaller than those of survi-
vors at the same stage of tumour growth. It therefore seems
unlikely that the high mortality in these experiments
influenced their outcome, although it provided clear evidence
that the degree of warfarin treatment was as intensive as
could be achieved. In summary, these studies provide evi-
dence that warfarin can inhibit metastasis in an animal
model of cancer without directly or indirectly inhibiting the
growth of the primary tumour. Further studies are required
to determine the role of the anticoagulant properties of the
drug in this effect.
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